SEC Tracker
Get the app

aTYR PHARMA ATYR

aTYR PHARMA: reports an executive or board change, amends its charter or bylaws and reports shareholder vote results

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Reports shareholder vote results (5.07)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when aTYR PHARMA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Arvinas ARVN public float $469M, Jun 30, 2025
  2. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  3. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  4. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  5. Myriad Genetics MYGN public float $494M, Jun 30, 2025